###### Strengths and limitations of this study

-   This is the first systematic review to synthesise cost-effectiveness evidence on all types of interventions (policy, clinical or behavioural) to control cardiovascular diseases and diabetes mellitus in South Asia.

-   This review used a rigorous and broad search strategy including a wide range of sources to ensure all published studies are included for review.

-   This review used explicitly stated methods (protocol paper published) and standard checklists to assess methodological quality of studies.

-   The search was confined to English language publications performed as of August 2016, and this review excluded unpublished and 'grey' literature domain as we wanted to include studies that have undergone peer review process.

-   Significant heterogeneity in analytical framework and outcome measures used in these studies restricted meta-analysis and direct ranking of the interventions by their degree of cost-effectiveness.

Introduction {#s1}
============

Evidence from randomised trials suggests that both pharmacological and non-pharmacological strategies are important in prevention and management of cardiovascular diseases (CVD) and diabetes mellitus (DM).[@R1] While there is strong evidence on cost-effectiveness of pharmaceutical and lifestyle interventions in reducing the CVD and DM risk in affluent settings,[@R13] little is known about the comparative cost-effectiveness of various interventions to control CVD and DM in South Asia. To generalise results from high-income countries to low and middle-income countries (LMICs) is not entirely justified because reasonable thresholds for cost-effectiveness will vary markedly---as will affordability. Also, setting specific cost-effectiveness information is important because of the differences in healthcare infrastructure.

With the rapidly increasing prevalence of CVD and DM in South Asia and the consequent huge economic losses, coupled with ill-equipped health systems and scarce resources to tackle the burden of chronic conditions, it is imperative to promote the most cost-effective interventions in this region. While a large number of economic evaluations have been recently performed in context to LMICs, and some authors have reviewed the available literature on non-communicable diseases broadly,[@R17] no systematic attempt has been made so far to compile the evidence base and appraise the methodological quality of the economic evaluations of interventions to control CVD and DM in South Asia. To the best of our knowledge, no review has considered the cost-effectiveness evidence of interventions to control CVD and DM simultaneously, although these diseases share common risk factors.

We systematically reviewed the cost-effectiveness evidence on individual-level, group-level and population-level interventions to control CVD and DM in South Asia. The specific objectives were the following:to summarise the incremental resource use, costs, consequences and cost-effectiveness of interventions versus comparators to control CVD and DM in South Asiato describe the quality of economic evaluations considering key methodological issues.

Research design and methods {#s1a}
---------------------------

A protocol for the systematic review has been published previously and it provides a detailed description of the methodology, used for the current study.[@R19] The systematic review has been registered previously in PROSPERO (CRD42013006479).

Briefly, we searched for studies that met the following inclusion criteria:type of studies: full economic evaluations (cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis) based on randomised trials or observational studies or decision modelstype of participants: studies that included individuals with either established DM or CVD or at risk of developing these diseases in one of the South Asian countries: Afghanistan, Bangladesh, Bhutan, India, Pakistan, Maldives, Nepal and Sri Lankatypes of interventions: interventions or strategies for prevention and treatment of CVD or DM as documented in the previously published protocol[@R19]types of outcome measures: we included several outcomes broadly under three domains---resource use, costs and cost-effectiveness as incremental cost per quality-adjusted life years (QALYs) gained, or disability-adjusted life years (DALYs) averted, or life years gained or intermediate outcomes; a detailed list has been presented in the previously published protocol[@R19]studies published in the English language.

We searched 14 electronic databases and hand-searched for publications of the Disease Control Priorities Project 2 (DCPP2) and the WHO-Choosing Interventions that are Cost-Effective (WHO-CHOICE) to identify relevant studies. The details of the databases searched and a search strategy are provided in [supplementary web appendix 1](#SP1){ref-type="supplementary-material"}.
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Critical appraisal of included studies {#s1b}
--------------------------------------

Checklists proposed by Drummond *et al*,[@R20] Evers *et al*[@R21] and Philips *et al*[@R22] were used for data extraction and to review methodological quality and strength of economic evidence. Also, we looked for funding sources of included studies.

Analysing, interpreting and reporting results {#s1c}
---------------------------------------------

We extracted the incremental cost, incremental effect and incremental cost-effectiveness ratios (ICER) for interventions evaluated in the eligible studies. To adjust for cost and varying currencies over time, we used country-specific consumer price inflation rate to present value in 2017 and then used midyear currency conversion.[@R23] All costs were converted to US\$ (2017). Data extraction and critical appraisal of included studies were conducted by two authors independently and differences if any were resolved by consensus.

We used country-specific gross domestic product (GDP) per capita threshold, as per WHO guidelines,[@R25] to interpret the ICER for all interventions evaluated in this review. We colour-coded ICER estimates as per the following scheme:green=ICER\<1×GDP per capita per QALY gained (*highly cost-effective*)yellow=1--3×GDP per capita per QALY gained (*cost-effective*)red=ICER\>3×GDP per capita per QALY gained (*not cost-effective*).

Interventions that resulted in a negative incremental effect were regarded as dominated strategy and no ICER was reported. Further, we synthesised the cost-effectiveness data and presented the ICER for policy or clinical interventions, separately in the following categories: primordial, primary, secondary and tertiary prevention.

Difference between protocol and full review {#s1d}
-------------------------------------------

We have not planned to include economic evaluations based on observational studies in the protocol but we have included it in our review. The more inclusive criteria enabled us to provide a more comprehensive review of the evidence base surrounding the topic. Risk of bias assessment in randomised trials was not conducted using Cochrane methods as Drummond and Evers checklists are inclusive of methodological quality assessments of economic evaluations alongside randomised trials as well.

Results {#s2}
=======

Search results {#s2a}
--------------

Our first search yielded 2949 items, titles and abstracts screening resulted in 85 articles, and full-text screening provided 42 articles that met full inclusion criteria ([figure 1](#F1){ref-type="fig"}).
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Characteristics of included studies {#s2b}
-----------------------------------

[Table 1](#T1){ref-type="table"} shows the detailed description of the studies (n=42) by country/setting, study population, intervention(s), comparator(s), economic perspective and type of analysis, and outcome measures.

###### 

Description of the economic evaluations and risk of bias assessment in the included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source (author, year)                 Country\                    Study population                                                                                          Intervention                                                                                                                                                                                            Comparison                                                                     Economic perspective               Methodology                     Outcome measure studied                                                                                                                                        Risk of bias assessment
                                        /Setting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ------------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Turi *et al*, 1991[@R53]              India                       40 patients with severe rheumatic mitral stenosis                                                         Percutaneous balloon commissurotomy                                                                                                                                                                     Surgical closed commissurotomy                                                 Not stated\                        RCT-based CCA                   Costs compared vs haemodynamic stability in both arms                                                                                                          Source of treatment effect: single-centre RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (direct medical costs)                                                                                                                                                                                                            Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: cost-consequences analysis was conducted; incremental cost-effectiveness ratio between treatment groups not reported; long term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Ahuja *et al*, 1997[@R54]             India                       Patients with mild hypertension                                                                           Antihypertensive regimens with diuretics                                                                                                                                                                Antihypertensive regimens without diuretics                                    Patient                            RCT-based CEA                   Mean cost of control of BP to target levels per patient per day in control and study groups                                                                    Source of treatment effect: single-centre RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: only drug costs included in the analysis\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; only drug costs were compared for BP control; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Nanjappa\                             India                       912 patients with symptomatic rheumatic mitral stenosis                                                   Transvenous mitral commissurotomy: double-lumen (Accura) variable-sized single balloon                                                                                                                  Triple-lumen (Inoue) balloon                                                   Not stated\                        Observational study-based CCA   Costs compared vs haemodynamic stability in both arms                                                                                                          Source of treatment effect: hospital-based observational study, presurgery and postsurgery effects on haemodynamic stability reported\
  *et al*, 1998[@R55]                                                                                                                                                                                                                                                                                                                                                                                                                                                (direct medical costs)                                                                                                                                                                                                            Source of cost data: local hospital-level direct medical costs were included\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: cost-consequences analysis was conducted; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Malhotra\                             India                       Patients with unstable angina                                                                             Enoxaparin                                                                                                                                                                                              UFH                                                                            Healthcare provider                RCT-based CCA                   Mean cost per patient in UFH and enoxaparin groups                                                                                                             Source of treatment effect: single-centre RCT\
  *et al*, 2001[@R56]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: cost-consequences analysis was conducted; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Murray *et al*, 2003[@R57]            South Asia region (India)   High CV risk individuals                                                                                  Behavioural interventions and treatment strategies to lower SBP and cholesterol                                                                                                                         Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reduction in CVD risk                                                                                                                         Source of treatment effect: systematic review and meta-analysis of RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: WHO-CHOICE database\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: state transition population cohort model

  Chisholm\                             South Asia region (India)   Individuals at risk of alcohol and tobacco use                                                            Interventions to reduce use of alcohol and tobacco use                                                                                                                                                  Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reducing use of tobacco, alcohol and illicit drug                                                                                             Source of treatment effect: systematic review of observational study\
  *et al*, 2004[@R15]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: WHO-CHOICE database\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: state transition population cohort model

  Namboodiri\                           India                       Patients awaiting pacemaker implant                                                                       DDD vs VDD pacemakers                                                                                                                                                                                   --                                                                             Not stated\                        Observational study-based CCA   Costs compared vs clinical efficacy and complications between two arms                                                                                         Source of treatment effect: hospital-based observational study, presurgery and postsurgery effects on haemodynamic stability and complications reported\
  *et al*, 2004[@R58]                                                                                                                                                                                                                                                                                                                                                                                                                                                (direct medical costs)                                                                                                                                                                                                            Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: cost-consequences analysis was conducted; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Narayan\                              South Asia region (India)   Patients at risk of developing diabetes or patients with diabetes                                         Combination of treatment and screening strategies to prevent and manage diabetes                                                                                                                        Various                                                                        Healthcare provider                Decision model-based CEA        QALYs gained by preventing and/or treating diabetes and its complications                                                                                      Source of treatment effect and cost data: extrapolated from developed countries; it was assumed that costs are eight times higher in developed countries than in low-income and middle-income countries; treatment effects (QALYs) were taken same as observed in the developed countries\
  *et al*, 2006[@R34]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Type of EE/decision model appropriate: not much details provided to ascertain appropriateness of model fit\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: no details provided

  Gaziano\                              South Asia region (India)   Patients with high CV risk or established CVD                                                             Interventions to manage CVD                                                                                                                                                                             Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by treating and preventing CVD events                                                                                                            Source of treatment effect: derived from meta-analysis of RCT; disability weights taken from GBD study 2006 report\
  *et al*, 2006[@R43]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: not clear\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE/decision model and assumptions appropriate: not much details provided to ascertain appropriateness of model fit

  Willett *et al*, 2006[@R5]            South Asia region (India)   Population at risk                                                                                        Dietary and LSM strategies                                                                                                                                                                              Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reducing CVD risk                                                                                                                             Source of treatment effect: systematic review and meta-analysis of RCTs\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: no details provided\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE/decision model and assumptions appropriate: not much details provided

  Rodgers\                              South Asia region (India)   Population at risk                                                                                        Multidrug regimen to reduce high blood pressure and cholesterol                                                                                                                                         Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reducing CVD risk                                                                                                                             Source of treatment effect: derived from meta-analysis of RCTs of BP-lowering treatment; DALYs weight obtained from GBD 2000 study\
  *et al*, 2006[@R59]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: annual medications cost derived from International Drug Price Indicator Guide\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Medical services: Xact Medicare Services 2003 + WHO-CHOICE\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: no details provided

  Jha *et al*, 2006[@R60]               South Asia region (India)   Population at risk                                                                                        Interventions to reduce tobacco use                                                                                                                                                                     Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reducing tobacco use and preventing tobacco attributed deaths                                                                                 Source of treatment effect: systematic review and meta-analysis of 139 observational studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: no details provided\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: static cohort model

  Shafiq *et al*, 2006[@R61]            India                       Patients with unstable angina                                                                             Low molecular-weight heparins---enoxaparin, nadroparin and dalteparin                                                                                                                                   Active comparators                                                             Patients and healthcare provider   RCT-based CEA                   ICER per MACE outcomes (MI, recurrent angina, death)                                                                                                           Source of treatment effect: single-centre RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; since no difference in treatment effects was observed in the trial, an appropriate choice of economic analysis would be cost-minimisation analysis\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Ramachandran\                         India                       Individuals with impaired glucose tolerance                                                               LSM, metformin                                                                                                                                                                                          No intervention                                                                Healthcare provider                RCT-based CEA                   NNT to prevent or delay once incident case of diabetes                                                                                                         Source of treatment effect: single RCT\
  *et al*, 2007[@R37]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: patients, health facility and program-level and societal costs included during the trial period\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Zubair Tahir *et al*, 2009[@R62]      Pakistan                    55 patients with aneurysmal subarachnoid haemorrhage                                                      Endovascular treatment post subarachnoid haemorrhage                                                                                                                                                    Surgical clipping post subarachnoid haemorrhage                                Not stated\                        Observational study-based CCA   Costs compared vs circulation aneurysms between two arms                                                                                                       Source of treatment effect: hospital-based observational study, presurgery and postsurgery effects on haemodynamic stability reported\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (direct medical costs)                                                                                                                                                                                                            Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: cost-consequences analysis was conducted; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Habib *et al*, 2010[@R63]             Bangladesh                  Patients with diabetes nephropathy with at least 1 year of follow-up                                      Medical intervention for diabetic nephropathy                                                                                                                                                           Late-detected vs early-detected diabetic nephropathy                           Patients/healthcare provider       Observational study-based CEA   Cost of treating early-detected and late-detected diabetes nephropathy was compared against the clinical outcomes: HbA1c, creatinine, BP, FBG, lipid profile   Source of treatment effect: hospital-based observational study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: Local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Habib *et al*, 2010[@R64]             Bangladesh                  Patients with diabetes foot                                                                               Medical intervention for diabetic foot management                                                                                                                                                       Late-detected vs early-detected diabetic foot                                  Patients/healthcare provider       Observational study-based CEA   Cost of treating early-detected and late-detected diabetes foot was compared against the clinical outcomes: HbA1c, creatinine, BP, FBG, lipid profile          Source of treatment effect: hospital-based observational study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Sanmukhani,\                          India                       Patients at risk of CVD (primary prevention)\                                                             Simvastatin---40 mg\                                                                                                                                                                                    No therapy                                                                     Patient                            Observational study-based CEA   Cost per major coronary event averted\                                                                                                                         Source of treatment effect: derived from published RCTs and observational studies\*\
  *et al*, 2010[@R65]                                               Patients with history of CVD\                                                                             Pravastatin---40 mg                                                                                                                                                                                                                                                                                                                                       Cost per CHD death averted                                                                                                                                     Source of cost data: local hospital-level costs data collected\
                                                                    (secondary prevention)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Type of EE appropriate: only average cost-effectiveness ratio was reported; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Cecchini *et al*, 2010[@R32]          South Asia region (India)   Population-based and individuals at high risk (BMI≥25 kg/m^2^, high BP, cholesterol, diabetes)            Dietary and physical activity interventions targeted at:\                                                                                                                                               No intervention                                                                Healthcare provider                Decision model-based CEA        Reduction in BMI, cholesterol, SBP, fat intake and increase in fibre consumption                                                                               Source of treatment effect: distribution of risk factors in population obtained from WHO mortality database, UN statistics,\
                                                                                                                                                                              1. school level\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         US NHANES survey, Health Survey for England; treatment effects derived from Women's Healthy Eating and Living randomised trial and the Seven Countries Study\
                                                                                                                                                                              2. worksites\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Disability weights---GBD study 2006\
                                                                                                                                                                              3. mass media campaigns\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Source of cost data: WHO-CHOICE database\
                                                                                                                                                                              4. fiscal measures\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Type of EE appropriate: yes\
                                                                                                                                                                              5. physician counselling\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Decision model and assumptions appropriate: chronic disease prevention model
                                                                                                                                                                              6. food advertising regulation\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                              7. food labelling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Schulman-Marcus *et al*, 2010[@R40]   India                       Patients with acute coronary syndrome                                                                     Prehospital ECG performed by a GP to improve timely access to reperfusion by accurate referral to a hospital                                                                                            ECG-based diagnosis vs no ECG tests in acute chest pain                        Societal                           Decision model-based CEA        QALY gained by accurate referral to hospital in patients with ACS                                                                                              Source of treatment effect: relative risk reduction with thrombolytics derived from systematic review and meta-regression analysis of trials; QALY weight derived from DCP2, 2006 and GBD study 2006 reports\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ECG cost---local Central Government Health Scheme rates in India\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Drug prices: International Drug Price Indicator Guide\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Medical services: cost derived from Disease Control Priorities Project\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: Markov model

  Donaldson\                            India                       Individuals at risk of secondhand smoking                                                                 Prohibition of smoking in public places                                                                                                                                                                 No smoking ban                                                                 Societal                           Decision model-based CEA        Life years saved and QALYs gained by complete smoking ban in public places and by averted AMI                                                                  Source of treatment effect: derived from systematic review and meta-analysis of observational study\
  *et al*, 2011[@R30]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Source of cost data: local state records+WHO-CHOICE database\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: model structure not described and ICER calculation looks ambiguous

  Lohse *et al*, 2011[@R66]             India                       Women with gestational diabetes                                                                           Screening programme for GDM to prevent T2DM                                                                                                                                                             No screening                                                                   Societal                           Decision model-based CEA        DALYs averted by preventing T2DM                                                                                                                               Source of treatment effect: derived from two RCTs\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: primary cost data collected from four service delivery sites in India\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: GDM model

  Jafar *et al* 2011[@R36]              Pakistan                    Individuals with high blood pressure                                                                      Community-based interventions for BP control:\                                                                                                                                                          Usual care                                                                     Societal                           RCT-based CEA                   ICER per reduction in SBP and\                                                                                                                                 Source of treatment effect: community-based cluster RCT\
                                                                                                                                                                              1. combined HHE plus trained GP\                                                                                                                                                                                                                                                                                                                          DALYs averted by reducing CVD events                                                                                                                           Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                              2. HHE only\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Type of EE appropriate: yes\
                                                                                                                                                                              3. trained GP only                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Ahmad *et al*, 2011[@R67]             India                       Patients with diabetes undergoing surgery                                                                 Different insulin regimens for patients with diabetes undergoing surgery\                                                                                                                               Active comparators                                                             Patient                            RCT-based CEA                   ICER for different insulin regimens for reduction in perioperative complications                                                                               Source of treatment effect: hospital-based RCT, although randomisation method is not clearly described\
                                                                                                                                                                              1. pre-mixed regular/NPH (30:70)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                              2. split-mixed regular/NPH\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Type of EE appropriate: yes\
                                                                                                                                                                              3. split-mixed glargine/lispro\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Decision model and assumptions appropriate: NA
                                                                                                                                                                              4. split-mixed detemir/aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Humaira *et al*, 2012[@R68]           Bangladesh                  Patients with DR with at least 1 year of follow-up                                                        Medical intervention for diabetic retinopathy                                                                                                                                                           Late-detected vs early-detected diabetic retinopathy                           Patient/healthcare provider        Observational study-based CEA   Cost of treating early-detected and late-detected DR was compared against the clinical outcomes: HbA1c, creatinine, BP, FBG, lipid profile                     Source of treatment effect: hospital-based observational study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Brown *et al*, 2013[@R31]             India                       School students: aged 14 years and above                                                                  Project MYTRI\                                                                                                                                                                                          No intervention                                                                Societal                           RCT-based CCA                   QALYs gained by averted smoking and medical costs                                                                                                              Source of treatment effect: single-cluster RCT\
                                                                                                                                                                              Four intervention components:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Source of cost data: programme-level costs data collected during the trial period\
                                                                                                                                                                              1. classroom activities/behavioural interventions\                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                              2. peer-led health activism\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Decision model and assumptions appropriate: Markov model was used to project the short-term outcomes observed within the cluster RCT
                                                                                                                                                                              3. posters\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                              4. parent cards                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Ortegón *et al*, 2012[@R29]           South Asia region (India)   Population-based and individuals at high CV risk                                                          123 single or combination prevention and treatment strategies for CVD, diabetes and smoking                                                                                                             Various                                                                        Healthcare provider                Decision model-based CEA        DALYs averted by reducing CVD, diabetes and tobacco related disease                                                                                            Source of treatment effect:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       tobacco interventions---derived from systematic review of observational study (cross-sectional and case--control study); tobacco tax effect---derived from US CDC, World Bank and WHO reports; salt reduction---analysis of observational data+data from trials of salt reduction; CVD drugs---derived from meta-analysis of RCTs; intensive glucose-lowering drugs derived from meta-analysis of RCTs; glycaemic control---UKPDS and DCCT studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: WHO-CHOICE database\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: population-based cohort model used local epidemiological data

  Marseille *et al*, 2013[@R35]         India                       Women with gestational diabetes                                                                           Screening programme for GDM to prevent T2DM                                                                                                                                                             No screening                                                                   Healthcare provider                Decision model-based CEA        DALYs averted by reducing perinatal complications and T2DM                                                                                                     Source of treatment effect: single RCT (IDPP-1 trial in India)+meta analysis of RCT; DALYs obtained from published literature sources (based on seven experts)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: GeDiForCE microsimulation model

  Rachapelle *et al*, 2013[@R27]        India                       Patients with diabetes aged 40 years who had not been previously screened for diabetic retinopathy (DR)   Telemedicine screening and hospital-based DR treatment                                                                                                                                                  No screening                                                                   Healthcare provider and societal   Decision model-based CEA        QALYs gained by preventing DR                                                                                                                                  Source of treatment effect: single multicentre RCT (ETDRS study); baseline distribution of population obtained from population survey in India\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: Markov model

  Megiddo *et al*, 2014[@R38]           India                       Patients with acute myocardial infarction                                                                 Policies that expand the use of aspirin, injectable streptokinase, beta-blockers, ACE inhibitors, and statins for treatment and secondary prevention of AMI                                             Active comparators                                                             Healthcare provider                Decision model-based CEA        DALYS averted by expanding use of CVD prevention drugs                                                                                                         Source of treatment effect: population distribution using World Bank population projection tables; life expectancy using WHO life tables; CHD incidence rates using published literature from India; baseline coverage of drugs for treatment of AMI obtained from CREATE registry and for secondary prevention of CVD therapy obtained from community-based survey PURE study in India; efficacy of aspirin obtained from ISIS-2; effectiveness of multidrug therapy obtained from prior literature sources (meta-analysis of RCTs); disability weights used from GBD 2006 report\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: Drug costs data obtained from cimsasia.com\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: Markov model

  Patel *et al*, 2014[@R69]             India                       Patients with hypertension                                                                                Nebivolol (2.5 mg, 5 mg, 10 mg)                                                                                                                                                                         Sustained release metoprolol succinate (25 mg, 50 mg, 100 mg)                  Patient                            RCT-based CEA                   ICER per unit reduction in blood pressure per day                                                                                                              Source of treatment effect: single RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Lamy *et al*, 2014[@R70]              Asia (India)                Patients at risk of CVD, with IGT/IFG, or type 2 diabetes mellitus                                        Insulin glargine                                                                                                                                                                                        Standard management of hyperglycaemia and n-3 fatty acids or placebo           Healthcare provider and patient    RCT-based CMA                   Cost per patient in insulin glargine arm vs standard care arm                                                                                                  Source of treatment effect: single multicentre RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Lamy *et al*, 2014[@R71]              Asia (India)                Patients requiring revascularisation procedure                                                            Off-pump CABG                                                                                                                                                                                           On-pump CABG                                                                   Healthcare provider and patient    RCT-based CMA                   Cost per patient in the off-pump CABG vs on-pump CABG group                                                                                                    Source of treatment effect: single multicentre RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Anchala *et al*, 2015[@R72]           India                       Patients with hypertension (30--64 years)                                                                 Decision support system for hypertension management                                                                                                                                                     Chart-based support for hypertension management                                Healthcare provider                RCT-based CEA                   Cost per unit reduction in SBP                                                                                                                                 Source of treatment effect: single-cluster RCT\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: primary costs data collected from health centre\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Dukpa *et al*, 2015[@R73]             Bhutan                      Population at risk of diabetes and hypertension                                                           WHO Package of Essential Non-Communicable (PEN) disease interventions for primary healthcare---current PEN programme vs universal screening for diabetes and hypertension                               No screening                                                                   Societal                           Decision model-based CUA        Cost per DALYs averted                                                                                                                                         Source of treatment effect/model parameters: transition probabilities used from published literature sources, population risk profile for hypertension and diabetes obtained from local surveys; treatment effects with BP-lowering drugs (controlled hypertension) obtained from meta-analysis of RCT; intervention effectiveness with intensive glucose and hypertension control obtained from CDC diabetes cost-effectiveness group; disability weights obtained from GBD study, WHO 2004\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local primary data collected by the authors, from 16 key informants; both direct medical and non-medical costs included\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: Markov model

  Basu *et al*, 2015[@R39]              India                       Population at risk of CVD and with existing CVD                                                           Expansion of national insurance to cover primary prevention, secondary prevention and tertiary treatment for CVD                                                                                        Active comparators                                                             Healthcare provider                Decision model-based CEA        Cost of treatment/prevention strategies coverage per DALY averted                                                                                              Source of treatment effect: current access to CVD therapy obtained from local survey in India (SAGE study); insurance coverage obtained from published literature (Rajiv Aarogyasri Community Health Insurance Scheme in Andhra Pradesh); disability weights obtained from GBD 2010 study; treatment effects of CVD drugs obtained from meta-analysis of RCTs\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: WHO-CHOICE database\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: validated microsimulation model

  Basu *et al*, 2015[@R74]              India                       Population at risk of diabetes                                                                            Alternative diabetes screening approaches: Chaturvedi risk score, Mohan risk score, Ramachandran risk score, random point of care glucose testing                                                       Active comparators                                                             Healthcare provider                Decision model-based CEA        Cost of implementing screening and confirmatory tests\                                                                                                         Source of treatment effect: population demographics obtained from UN database, distribution of risk factors for diabetes among Indians obtained from IMS study and several other data sources and combined using regression models; to estimate health benefits of screening, UKPDS outcomes model 2 having South Asian-specific disease progression parameters (validated among South Asians in UK and India) were used\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Cost per true positive case                                                                                                                                    Source of cost data: WHO-CHOICE database to include costs of personnel, operations and materials for screening\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: validated microsimulation model used

  Gupta *et al*, 2015[@R41]             India                       Patients with type 2 diabetes mellitus                                                                    Biphasic insulin aspart 30±OGLDs                                                                                                                                                                        Biphasic human insulin 30±OGLDs, insulin glargine±OGLDs or NPH insulin±OGLDs   Healthcare provider                Decision model-based CEA        Incremental cost per life years gained\                                                                                                                        Source of treatment effect: A~1~chieve study---an observational 24-week study in insulin-naïve and insulin-experienced population; utility weights (QALY) were derived from the same study using EQ5D\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Incremental cost per QALYs gained                                                                                                                              Source of cost data: existing literature, reviewed by experts; cost of insulin in OGLD obtained from local Novo Nordisk affiliates\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: validated IMS CORE Diabetes Model used and C/E results projected for 30 years' duration

  Home *et al*, 2015[@R75]              India                       Type 2 diabetes mellitus                                                                                  Basal insulin treatment with insulin detemir                                                                                                                                                            No insulin detemir (all OGLDs)                                                 Healthcare provider                Decision model-based CEA        Incremental cost per life years gained\                                                                                                                        Source of treatment effect: A~1~chieve study---an observational 24-week study in insulin-naïve and insulin-experienced population; utility weights (QALY) were derived from the same study using EQ5D\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Incremental cost per QALYs gained                                                                                                                              Source of cost data: existing literature, reviewed by experts; cost of insulin in OGLD obtained from local Novo Nordisk affiliates\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: validated IMS CORE Diabetes Model used and C/E results projected for 30 years' duration

  Sengottuvelu *et al*, 2016[@R76]      India                       65 patients requiring angiogram followed by fractional flow reserve                                       Fractional flow reserve                                                                                                                                                                                 Angiography                                                                    Not stated\                        Observational study-based CCA   Costs compared vs management decision                                                                                                                          Source of treatment effect: hospital-based observational study, presurgery and postsurgery effects on haemodynamic stability reported\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (direct medical costs)                                                                                                                                                                                                            Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Limaye *et al*, 2016[@R77]            India                       Type 2 diabetes mellitus                                                                                  Antidiabetic drugs (glimepiride, pioglitazone, metformin)                                                                                                                                               Active comparators                                                             Patient                            Observational study-based CEA   Cost per unit of effectiveness                                                                                                                                 Source of treatment effect: hospital-based observational study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: local hospital-level costs data collected\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: no; incremental cost-effectiveness ratio between treatment groups not reported; long-term outcomes not assessed\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: NA

  Basu *et al*, 2016[@R78]              India                       Individuals aged 30--70 years at high CV risk (≥10%)                                                      A treat-to-target strategy emphasising lowering blood pressure to a targetA benefit-based tailored treatment strategy emphasising lowering CVD riskA hybrid strategy currently recommended by the WHO   Active comparators                                                             Healthcare provider                CEA                             DALYS averted by reducing CVD deaths                                                                                                                           Source of treatment effect: meta-analysis of RCTs; adherence to prescribed therapy was obtained from observational cohort studies\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Source of cost data: drugs costs derived from International Drug Price Indicator Guide; WHO-CHOICE cost estimates for medical services updated to 2015 dollars\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Type of EE appropriate: yes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Decision model and assumptions appropriate: validated microsimulation model
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*West of Scotland Coronary Prevention Study, the Air Force Coronary Atherosclerosis Prevention Study and the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm study for primary prevention; the Cholesterol and Recurrent Events Trial, the Long-term Intervention with Pravastatin in Ischaemic Disease Study and the Scandinavian Simvastatin Survival Study (4S) for secondary prevention; and two studies, the Heart Protection Study and the Pravastatin in elderly individuals at risk of vascular disease (PROSPER) study for high-risk patients.

ACEi, ACE inhibitors; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft surgery; CCA, cost-consequences analysis; CDC, Centers for Disease Control and Prevention; CEA, cost-effectiveness analysis; CHD, Coronary Heart Disease; CORE, Centre for Outcomes Research; CREATE, Treatment and outcomes of acute coronary syndromes in India; CUA, cost-utility analysis; CV, cardiovascular; CVD, cardiovascular diseases; C/E, Cost-effective; DALY, disability-adjusted life years; DCCT, Diabetes Control and Complications Trial; DCP2, Disease Control Priorities; DDD, a type of heart pacemake that is Dual pacing for both chambers, Dual chamber activity sensing, and Dual response; DR, diabetes retinopathy; ECG, echocardiogram; EE, economic evaluation; EQ5D, European Quality of Life 5 Dimension; ETDRS, Early Treatment for Diabetic Retinopathy Study; FBG, Fasting Blood Glucose; GBD, Global Burden of Disease; GDM, gestational diabetes mellitus; GP, general practitioner; HbA1c, glycated haemoglobin; HHE, home health education; ICER, incremental cost-effectiveness ratio; IDPP-1, Indian Diabetes Prevention Program trial 1; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose Tolerance; ISIS-2, Second International Study of Infarct Survival; LSM, lifestyle modifications; MACE, major adverse cardiovascular events; MI, myocardial infarction; MYTRI, Mobilizing Youth for Tobacco-Related Initiatives in India; NA, not available; NHANES, National Health and Nutrition Examination Survey; NNT, Number Needed to Treat; NPH, neutral protamine Hagedorn; OGLD, oral glucose-lowering drugs; PURE, Prospective Urban Rural Epidemiology Study; QALYs, quality-adjusted life years; RCT, randomised controlled trials; SAGE, Study on Global AGEing and Adult Health; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; UFH, unfractionated Heparin; UKPDS, United Kingdom Prospective Diabetes Study; UN, United Nations; VDD, Ventricular Dual Chamber heart pacemaker; WHO-CHOICE, Choosing Interventions that are Cost-Effective.

### Study design {#s2b1}

The economic evaluations were based on observational studies (n=9), randomised controlled trials (RCT) (n=12) and decision models (n=21).

### Study setting {#s2b2}

Most studies were from India (n=37), followed by Bangladesh (n=3), Pakistan (n=2) and Bhutan (n=1). Decision modelling studies had used effectiveness data mostly from meta-analysis of RCTs that reported results from developed countries.

### Study population {#s2b3}

Individuals (or population) at risk or with established CVD or DM were included.

### Intervention targets and comparators {#s2b4}

Three hundred and one interventions (policy, clinical or behavioural) were evaluated against null scenario (no intervention) or active comparators.

### Perspective {#s2b5}

In two-thirds of the studies (n=28), the authors explicitly documented and justified the economic perspective of the study. The studies used '*health system'*, that is, direct costs incurred by the health system (n=26); '*patient*', that is, out-of-pocket payments by patient (n=6); or '*societal'*, that is, inclusive of all direct and indirect costs, plus productive loss (n=6) perspectives. Five studies did not state any perspective.

### Funding {#s2b6}

Two-thirds of evaluations (n=29) provided statements on the funding source. Public sponsorship or charitable trust/foundation grant was most common (n=16), followed by pharmaceutical industry (n=6) or received no support (n=7). A large number of studies did not state their source of research funding (n=13).

### Resource use and costs {#s2b7}

Only 20% of the studies (n=8) reported types and quantities of resource use and unit costs separately. Of these, five were RCT-based economic evaluations and two were decision model studies, suggesting that RCT provides an advantage on the reporting of actual resource use data as it is being collected during the trial.

Mostly direct medical costs were considered, although the scope of this varied enormously. For instance, 14 studies included only cost of intervention (medicines, diagnostics), while others (n=28) included cost of training, delivery of intervention, associated healthcare visit costs and travel cost of patients to the healthcare facility. Most (n=27) appeared to use an 'ingredients' costing approach, where costs were broken down between the main cost components such as medications, healthcare visits, vehicles, salaries and consumables. Fewer (n=5) used an 'activity'-based approach, by identifying specific tasks such as programme and therapy costs. Two studies appeared to use some combination of the two, and it was not possible to discern the approach for eight papers. Few studies (n=6) also included 'productivity losses' (often termed 'indirect costs') in their assessment of costs, which were measured using the 'human capital approach'.

Regardless of the approach taken, most papers (n=21) presented aggregated cost information. Many studies used actual expenditure data (n=17) as their source of costs data. Seven studies used published sources to generate cost estimates sometimes supplemented with expert opinion. Currencies reported were mostly in US\$ (n=25), international dollars (n=4) or local currencies (Indian rupees/Bhutanese rupees) (n=6). In addition, seven studies quoted costs in both US\$ and the local currency.

### Outcome measures (consequences) {#s2b8}

Nearly half of the studies (n=21) used 'life years gained' or 'QALYs' or 'DALYs' in their analysis. The calculation of QALYs/DALYs was based on South Asian population life expectancies; however, the utility values (QALYs weight) were derived from developed countries. Disability weights used in the WHO-CHOICE-based decision model studies were derived from the Global Burden of Disease (GBD) study (2000).[@R26] The remaining studies reported intermediate outcome measures such as number needed to treat, length of hospital stay, hospitalisation rate, blood pressure (BP) reduction or CVD events avoided, which are easier to measure but harder to compare across interventions. None of the studies expressed outcomes (benefits) in monetary units.

### Time horizon {#s2b9}

Three-fourths of studies (n=31) explicitly stated their analytical time horizon. Eighty per cent of decision model studies adopted lifetime horizon and others reported cost-effectiveness estimates for 10, 20, 25, 30 or 50 years. RCT/observational studies-based economic evaluations had a median time horizon of 1 year.

### Discounting {#s2b10}

A discount rate of 3% was most often used for both costs and effects in decision model studies. RCT-based economic evaluations used a discount rate of 3% (n=3) and 5% (n=1). Further, 11 studies did not apply any discount rate.

### Analytical approach {#s2b11}

Cost-effectiveness analysis or cost-utility analysis were the main methods (n=34), followed by cost-consequences analysis (n=6) and cost-minimisation analysis (n=2). Although several of these papers (n=8) described themselves as cost-effectiveness analysis, they were in fact cost-consequences analysis or cost-minimisation analysis because an incremental analysis was not reported or there was no significant difference in the effectiveness of the intervention versus comparator, respectively. Most studies reported average cost-effectiveness ratio and interpreted it as ICER against the comparator as null scenario, that is, no intervention.

We found several different types of decision models used for cost-effectiveness analysis. A large majority of the studies used the WHO-CHOICE state transition model. Others used coronary heart disease (CHD) policy model, GeDiForCE, IMS Centre for Outcomes Research Diabetes Model, Centers for Disease Control and Prevention (CDC) model, Markov model or individual microsimulation model. Few studies provided details of model validation.

### Sensitivity analyses and generalisability of study results {#s2b12}

Nearly half of the studies (n=25) undertook some form of sensitivity analysis to assess the robustness of their findings to assumptions about input parameters. Of these, one-way sensitivity analysis was most often applied. Two studies used threshold analysis and one performed a multi-way sensitivity analysis. None considered the structural variations in the decision model for sensitivity analysis. Few studies described the model validation methods.

Three-quarters of the studies (n=32) discussed the generalisability issue. Efforts were largely confined to stating the limitations of the study, such as whether randomisation was employed or noting one or two facts about the study site which might limit generalisability to other contexts. Another 12 studies discussed issues of affordability but in brief terms, for example, by noting that the available budget should be taken into account (most studies focused on the cost-effectiveness without considering the budget impact/constraint) or by questioning the sustainability of a novel service such as a mobile diabetic retinopathy services, where there are already existing health services.[@R27]

Risk of bias assessment {#s2c}
-----------------------

In our critical review of methods used in economic evaluations to assess risk of bias, we found that almost all economic evaluations based on observational study only presented costs and consequences of two treatment strategies separately, without reporting an ICER or employed sensitivity analysis to assess robustness of costs or treatment effect estimates. Also, estimates of treatment effects from the observational studies are not very reliable due to the limitations in the original study design. On the other hand, economic evaluations based on RCTs reported better economic outcomes, that is, ICERs; however, these studies were limited by short follow-up duration (30 days to 1 or 2 years), treatment effects assessed as intermediate clinical outcomes (BP reduction, number needed to prevent one DM case) and mostly direct medical costs from health system perspective or patient perspective were reported, which ignores the societal costs and productivity loss due to illness. Lastly, decision modelling studies reported ICER per QALY gained or DALY averted mostly using the WHO-CHOICE methods, Markov models or microsimulation models from societal or health system perspectives. Many of the decision model studies from DCPP did not report the source of costs data, source of QALY weights and details on decision model structure or validation methods. Further, most of the WHO-CHOICE-based generalised cost-effectiveness analysis used disability weights from an earlier version of the GBD study (2000). Therefore, findings from this review should be used with caution for local decision making, and there is an urgent need for more investment in local research to generate evidence/data on costs of treatment and health services and effectiveness of interventions ([table 1](#T1){ref-type="table"}).

Methodological quality: summary {#s2d}
-------------------------------

[Figures 2 and 3](#F2 F3){ref-type="fig"} report the overall quality of studies based on the key methodological issues and technical characteristics for decision model studies, respectively. In general, very few studies reported quantities of resource use data and unit costs separately, details of statistical tests used and CI around ICER estimates. Among decision model studies, none reported methods used to assess methodological, structural or heterogeneity uncertainties, and very few discussed model validation methods. Critical appraisal of studies revealed that there were 15 excellent (++), 18 good (+) and 9 poor quality studies (−) ([table 2](#T2){ref-type="table"}).

![Methodological quality of included studies. This figure presents the number of studies meeting the key methodological quality metrics of economic evaluations as recommended in the standard checklists.](bmjopen-2017-017809f02){#F2}

![Technical characteristics of decision modelling studies. This figure presents the number of decision modelling studies meeting the key methodological criteria for decision modelling studies as proposed by Philips *et al.*[@R22]](bmjopen-2017-017809f03){#F3}

###### 

Technical characteristics of included studies and quality grading (strength of evidence)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source (author, year)                 Institution(s) conducting the study                                                                                                                                                                                                                                  Funding agency                                                                                               Currency, year             Choice of decision model and key parameters                                                                                             Time horizon                                               Discount rate used                          Incremental analysis reported   SeA done     Quality grading† (++, +, −)
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------- ------------------------------- ------------ -----------------------------
  Turi *et al*, 1991[@R53]              Nizam's Institute of Medical Sciences Hyderabad, India                                                                                                                                                                                                               Not stated                                                                                                   US\$, 1988                 Cost comparison/consequences analysis                                                                                                   NA                                                         NA                                          NA                              NA           −

  Ahuja *et al*, 1997[@R54]             King George's Medical College, Lucknow, India                                                                                                                                                                                                                        Not stated                                                                                                   Rupee, 1997                RCT-based CEA                                                                                                                           6 months                                                   NA                                          Yes                             No           \+

  Nanjappa *et al*, 1998[@R55]          Sri Jayadeva Institute of Cardiology, Bangalore, India                                                                                                                                                                                                               Not stated                                                                                                   US\$, 1996                 Cost comparison/consequences analysis                                                                                                   NA                                                         NA                                          NA                              NA           −

  Malhotra *et al*, 2001[@R56]          Nehru Hospital, Chandigarh, India                                                                                                                                                                                                                                    Not stated                                                                                                   Rupee and US\$, 1999       RCT-based CEA                                                                                                                           Hospital admission until discharge (5--7 days)             NA                                          Yes                             No           \+

  Murray *et al*, 2003[@R57]            WHO-CHOICE                                                                                                                                                                                                                                                           Not stated                                                                                                   Int\$, 2000                Standard multistate transition model tool with four states: PopMod was used to calculate DALY averted by reducing CVD risk              Lifetime                                                   3% for both costs and effects               Yes                             Yes          ++

  Chisholm *et al*, 2004[@R15]          WHO-CHOICE; University of Queensland, Australia; Centre for Addiction and Mental Health, Toronto, Canada                                                                                                                                                             Not stated                                                                                                   Int\$, 2004                Static State Transition decision model (generalised CEA)                                                                                Not stated\                                                3% for both costs and effects               Yes                             Yes          \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Namboodiri *et al*, 2004[@R58]        PGIMER, Chandigarh, India                                                                                                                                                                                                                                            Not stated                                                                                                   Rupee, 2001                Cost comparison/consequences analysis                                                                                                   NA                                                         NA                                          NA                              NA           −

  Narayan *et al*, 2006[@R34]           DCP2 Chapter                                                                                                                                                                                                                                                         Fogarty International Centre NIH, BMGF, WHO, World Bank                                                      US\$, 2001                 Cost-utility and cost-effectiveness analyses were based on published literature models; costs estimated from WHO-CHOICE resource        Not stated\                                                Not stated                                  Yes                             Not stated   \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Gaziano *et al*, 2006[@R43]           DCP2 Chapter                                                                                                                                                                                                                                                         Fogarty International Centre NIH, BMGF, WHO, World Bank                                                      US\$, 2001                 Population-based decision model; DALY weights taken from Mathers (2006)[@R79] and costs data from McFayden (2003)[@R80]                 Not stated\                                                Not stated                                  Yes                             Not stated   \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Willett *et al*, 2006[@R5]            DCP2 Chapter                                                                                                                                                                                                                                                         Fogarty International Centre NIH, BMGF, WHO, World Bank                                                      US\$, 2001                 Population-based decision model; authors have used local costs data and interventions benefits from published literature sources        Not stated\                                                Not stated                                  Yes                             Not stated   \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Rodgers *et al*, 2006[@R59]           DCP2 Chapter                                                                                                                                                                                                                                                         Fogarty International Centre NIH, BMGF, WHO, World Bank                                                      US\$, 2001                 Population-based decision model; authors have used local costs data and interventions benefits from published literature sources        Not stated\                                                Not stated                                  Yes                             Not stated   \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Jha *et al*, 2006[@R60]               DCP2 Chapter                                                                                                                                                                                                                                                         Fogarty International Centre NIH, BMGF, WHO, World Bank                                                      US\$, 2002                 Population-based decision model; authors have used local costs data and interventions benefits from published literature sources        Not stated\                                                Not stated                                  Yes                             Not stated   \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (assume: lifetime)                                                                                                                                  

  Shafiq *et al*, 2006[@R61]            PGIMER Chandigarh, India                                                                                                                                                                                                                                             Not stated                                                                                                   US\$ and rupee, 2004       RCT-based CEA                                                                                                                           Within trial analysis (30-day follow-up)                   NA                                          Yes                                          \+

  Ramachandran *et al*, 2007[@R37]      IDRF, Chennai, India                                                                                                                                                                                                                                                 Not stated                                                                                                   Rupee and US\$, 2006       RCT-based CEA                                                                                                                           Within trial analysis\                                     No discounting                              Yes                             Yes          ++
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (3 years)                                                                                                                                           

  Zubair Tahir *et al*, 2009[@R62]      Aga Khan University Hospital, Karachi, Pakistan                                                                                                                                                                                                                      Not stated                                                                                                   US\$, 2007                 Cost comparison/consequences analysis                                                                                                   NA                                                         NA                                          NA                              NA           −

  Habib *et al*, 2010[@R63]             Health Economics Unit, Diabetic Association of Bangladesh                                                                                                                                                                                                            None                                                                                                         US\$ (year not stated)     Retrospective hospital medical records-based economic analysis                                                                          NA                                                         NA                                          No                              NA           −

  Habib *et al*, 2010[@R64]             Health Economics Unit, Diabetic Association of Bangladesh                                                                                                                                                                                                            None                                                                                                         US\$ (year not stated)     Retrospective hospital medical records-based economic analysis                                                                          NA                                                         NA                                          No                              NA           −

  Sanmukhani *et al*, 2010[@R65]        Government Medical\                                                                                                                                                                                                                                                  Cadila Pharmaceutical, Ahmedabad, Gujarat, India                                                             Rupee, 2010                Published RCTs-based CEA                                                                                                                Not clear (variable as per the RCT selected for the CEA)   Not clear                                   Yes                             No           \+
                                        College, Gujarat, India; Postgraduate Institute of Medical Education and Research, Chandigarh, India                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Cecchini *et al*, 2010[@R32]          WHO-CHOICE; University of Queensland, Australia; Economic Analysis Unit, Mexico                                                                                                                                                                                      None                                                                                                         US\$, 2005                 Chronic disease prevention model---microsimulation                                                                                      50 years and lifetime horizon                              3% for both costs and effects               Yes                             Yes          ++

  Schulman-Marcus *et al*, 2010[@R40]   AIIMS, New Delhi; HSPH, New York                                                                                                                                                                                                                                     Sarnoff Cardiovascular Research Foundation, Fogarty International Centre NIH                                 US\$, 2007                 Markov model of urban Indian patients with acute chest pain presenting to a GP performing an ECG vs not performing one                  Lifetime                                                   3% for both costs and effects               Yes                             Yes          ++

  Donaldson *et al*, 2011[@R30]         PHFI and Johns Hopkins Bloomberg School of Public Health, Baltimore, USA                                                                                                                                                                                             None                                                                                                         US\$, 2008                 Details of model structure not provided, but assumptions and key parameters listed                                                      10 years and lifetime                                      3% for both costs and effects               Yes                             Yes          ++

  Lohse *et al*, 2011[@R66]             Novo Nordisk Denmark and UCSF                                                                                                                                                                                                                                        Novo Nordisk A/S.                                                                                            US\$, 2011                 GDModel decision tree                                                                                                                   Lifetime                                                   3% per year for costs;\                     Yes                             Yes          \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        effects not discounted, neither justified                                                

  Jafar *et al*, 2011[@R36]             AKU, Karachi, ICL, LSHTM                                                                                                                                                                                                                                             Wellcome Trust award                                                                                         US\$, 2007                 RCT-based CEA; benefits seen in BP reduction was converted to CV DALYs, using data from GBD study and using a linear regression model   10, 20, 50 years and lifetime                              5% for both costs and effects               Yes                             Yes          ++

  Ahmad *et al*, 2011[@R67]             MGMC-Sitapura, Jaipur                                                                                                                                                                                                                                                Not stated                                                                                                   US\$, 2010                 Observational study                                                                                                                     NA                                                         NA                                          Yes                             No           \+

  Humaira *et al*, 2012[@R68]           Department of Ophthalmology,\                                                                                                                                                                                                                                        None                                                                                                         US\$ (year not stated)     Retrospective hospital medical records-based economic analysis                                                                          NA                                                         NA                                          No                              NA           −
                                        BADAS, Bangladesh                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Brown *et al*, 2013[@R31]             University of Texas, Public Health Foundation of India                                                                                                                                                                                                               NIH grant                                                                                                    US\$, 2006                 RCT-based CEA and Markov model for long term cost-effectiveness                                                                         Lifetime, within trial                                     No                                          Yes                             Yes          \+

  Ortegón *et al*, 2012[@R29]           University of Columbia, University of Washington, WHO                                                                                                                                                                                                                None                                                                                                         Int\$, 2005                Chronic disease prevention model---WHO software DisMod II                                                                               Lifetime                                                   3% for both costs and effects               Yes                             Yes          \+

  Marseille *et al*, 2013[@R35]         Chennai Corporation Maternity Hospital referred GDM cases to Diabetes Care and Research Institute for antenatal monitoring and treatment                                                                                                                             Novo Nordisk A/S                                                                                             Int\$, 2011                Decision-analysis tool (the GeDiForCE) to assess cost-effectiveness                                                                     Lifetime                                                   3% for both costs and effects               Yes                             Yes          \+

  Rachapelle *et al*, 2013[@R27]        Sankara Nethralaya, Vision\                                                                                                                                                                                                                                          Sightsavers grant                                                                                            US\$, 2009                 Markov model\                                                                                                                           20 years, lifetime                                         3% for costs                                Yes                             Yes          \+
                                        Research Foundation, Chennai and LSHTM                                                                                                                                                                                                                                                                                                                                                                       (TreeAge Pro 2009)                                                                                                                                                                                                                                                                          

  Megiddo *et al*, 2014[@R38]           Centre for Disease\                                                                                                                                                                                                                                                  Bill and Melinda\                                                                                            US\$, 2014                 CHD cohort model                                                                                                                        Lifetime                                                   3%                                          Yes                             Yes          ++
                                        Dynamics, Economics, and Policy, Washington, DC, USA;\                                                                                                                                                                                                               Gates Foundation (Disease\                                                                                                                                                                                                                                                                                                                                                                                                          
                                        Public Health Foundation of India, New Delhi, India                                                                                                                                                                                                                  Control Priorities 3 Project)                                                                                                                                                                                                                                                                                                                                                                                                       

  Patel *et al*, 2014[@R69]             Shivrath Centre of Excellence in Clinical Research, Ahmedabad, India; UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, India; BJ Medical College, Ahmedabad, Gujarat, India                                                                          None                                                                                                         Rupee, 2007                RCT-based CEA                                                                                                                           Within trial analysis\                                     No discounting                              No                              No           \+
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (8 weeks)                                                                                                                                           

  Lamy *et al*, 2014[@R70]              McMaster University, Canada; AIIMS and Centre for Chronic Disease Control, New Delhi, India                                                                                                                                                                          Sanofi Aventis, Paris, France                                                                                US\$, 2014                 Randomised trial-based cost-minimisation analysis                                                                                       6.2 years---median trial duration                          3% for costs                                Yes                             Yes          ++

  Lamy *et al*, 2014[@R71]              McMaster University, Canada; University of Oxford, UK; AIIMS and Centre for Chronic Disease Control, New Delhi,\                                                                                                                                                     Canadian\                                                                                                    US\$, 2013                 Randomised trial-based cost-minimisation analysis                                                                                       1 year                                                     Not applicable                              Yes                             Yes          ++
                                        India; Charles\                                                                                                                                                                                                                                                      Institutes of Health Research grant                                                                                                                                                                                                                                                                                                                                                                                                 
                                        University, Prague, Czech Republic; Ankara University School of Medicine, Ankara, Turkey; and Unidade de Terapia Intensiva, Hospital do Coracao, Sao Paulo, Brazil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Anchala, *et al*, 2015[@R72]          Public Health Foundation of India, New Delhi, India; Centre for Chronic Disease Control, New Delhi, India; University of\                                                                                                                                            Wellcome Trust Capacity\                                                                                     Rupee and US\$             RCT-based CEA                                                                                                                           1 year                                                     3% for costs                                No                              Yes          \+
                                        Cambridge, UK; Department of\                                                                                                                                                                                                                                        Strengthening Strategic Award to the Public Health Foundation of India and a consortium of UK universities                                                                                                                                                                                                                                                                                                                          
                                        Epidemiology, Erasmus MC, Rotterdam, The Netherlands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Dukpa *et al*, 2015[@R73]             Ministry of Health, Royal Government of Bhutan\                                                                                                                                                                                                                      The Regional Office for South-East\                                                                          Bhutanese ngultrum, 2013   Markov model                                                                                                                            Lifetime                                                   3% for costs and effects                    Yes                             Yes          ++
                                        Health Intervention and Technology Assessment Program; Ministry of Public Health, Thailand; Mahidol University,\                                                                                                                                                     Asia of the WHO                                                                                                                                                                                                                                                                                                                                                                                                                     
                                        Bangkok, Thailand                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Basu *et al*, 2015[@R39]              Stanford University, USA; London School of Hygiene and Tropical Medicine, London, UK; University of Southern California, USA; National Bureau of Economic Research, Cambridge, Massachusetts, USA                                                                    The World Bank, Rosenkranz Prize for Healthcare Research                                                     US\$, 2014                 Microsimulation model of myocardial infarction and stroke in India                                                                      20 years                                                   3% for costs and effects                    Yes                             Yes          ++

  Basu *et al*, 2015[@R74]              Stanford University, USA; London School of Hygiene and Tropical Medicine,\                                                                                                                                                                                           Various federal funding support\*                                                                            US\$, 2014                 Microsimulation model                                                                                                                   10-year implementation horizon                             3% for costs                                No                              Yes          ++
                                        London, UK; Imperial College London, London, UK; Public Health Foundation of India; Veterans Affairs Hospital, Ann Arbor, Michigan, USA; University of Michigan, USA; University College London, London, UK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Gupta *et al*, 2015[@R41]             Jaslok Hospital and Research Centre, Mumbai, India; Pharmacoeconomics Centre of KSMC, Riyadh, Saudi Arabia; Novo Nordisk A/S, Søborg, Denmark; Universiti Sains Malaysia, Penang, Malaysia                                                                           Novo Nordisk                                                                                                 US\$, 2013\                IMS CORE\                                                                                                                               1-year, 30-year time horizon                               3% for costs and effect measures            Yes                             Yes          ++
                                                                                                                                                                                                                                                                                                                                                                                                                          Rupee, 2013                Diabetes Model                                                                                                                                                                                                                                                                              

  Home *et al*, 2015[@R75]              Newcastle University, Newcastle on Tyne, UK; University Guro\                                                                                                                                                                                                        Novo Nordisk                                                                                                 US\$, 2013\                IMS CORE\                                                                                                                               24-week follow-up\                                         3% for costs and effect measures            Yes                             Yes          ++
                                        Hospital, Seoul, South Korea; Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara, Mexico; Internal Medicine Department, University Hospital Setif, Setif, Algeria; Market Access -- Value Communication, Novo Nordisk A/S, Søborg, Denmark                                                                                                                Rupee, 2013                Diabetes Model                                                                                                                          1-year time\                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             30-year time horizon                                                                                                                                

  Sengottuvelu *et al*, 2016[@R76]      Apollo Hospitals, Chennai, India                                                                                                                                                                                                                                     Not stated                                                                                                   Rupee and US\$, 2014       Cost comparison/consequences analysis                                                                                                   NA                                                         NA                                          NA                              NA           −

  Limaye *et al,* 2016[@R77]            Hochschule Hannover, Hannover, Germany; Institute of\                                                                                                                                                                                                                Not stated                                                                                                   Rupee, 2016                Cross-sectional study-based CEA                                                                                                         No details provided                                        No discounting                              No                              No           −
                                        Chemical Technology, Mumbai, India                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Basu *et al*, 2016[@R78]              Stanford University, Stanford, California, USA; Harvard Medical School, Boston, USA; University College London, London, UK;\                                                                                                                                         Various federal funding support\*                                                                            US\$, 2015                 Decision modelling-based CEA                                                                                                            Lifetime                                                   3% for costs and effect measures            Yes                             Yes          ++
                                        University of Michigan, Ann Arbor, USA; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, USA; Imperial College London, London, UK;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                        Public Health Foundation of India, New Delhi, India                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Various federal funding support---the US National Institutes of Health; the Veterans Affairs Health Services Research and Development Service; the Rosenkranz Prize for Healthcare Research in Developing Countries; the International Development Research Centre of Canada; the NIHR Research Professorship award; and the Wellcome Trust Capacity Strengthening Strategic Award.

†Quality grading: ++ studies meeting all criteria on the checklists used for critical appraisal and provides *strong CE evidence* on interventions evaluated; + studies that fulfils some of the checklist criteria and provides *supportive evidence on CE*, which needs to be confirmed by future studies; − studies not meeting most criteria from the checklists used and so the *CE estimates are uncertain*.

AIIMS, All India Institute of Medical Sciences; AKU, Aga Khan University; BADAS, Bangla Bangladesh Diabetic Somiti (The Diabetic Association of Bangladesh); BMGF, Bill and Melinda Gates Foundation; BP, blood pressure; CE, Cost-effective; CEA, cost-effectiveness analysis; CHD, Coronary Heart Disease; CORE, Centre for Outcomes Research; CV, cardiovascular; CVD, cardiovascular diseases; DALY, disability-adjusted life years; DCP2, Disease Control Priorities-2 book; GBD, Global Burden of Disease; GDM, gestational diabetes mellitus; GP, general practitioner; HSPH, Harvard School of Public Health; ICL, Imperial College London; IDRF, India Diabetes Research Foundation; Int\$, international dollar; LSHTM, London School of Hygiene & Tropical Medicine; MGMC, Mahatma Gandhi Medical College; NA, not applicable; NIH, National Institutes of Health; PGIMER, Post Graduate Institute of Medical Education and Research; PHFI, Public Health Foundation of India; RCT, randomised controlled trials; SeA, sensitivity analysis; UCSF, University of California San Francisco; WHO-CHOICE, Choosing Interventions that are Cost-Effective.

Cost-effectiveness evidence {#s2e}
---------------------------

Interventions reviewed for their cost-effectiveness are grouped under the scheme of primordial, primary, secondary and tertiary prevention of CVD and DM ([table 3](#T3){ref-type="table"}). This flow is used to make information available in an accessible format for policy-level and clinical decisions. Cost-effectiveness results from observational studies have not been included in the final synthesis of cost-effectiveness data from South Asia due to poor quality of evidence. Cost-effectiveness data presented below are for India unless otherwise specified (the GDP per capita (in US\$ 2016) for India, Pakistan and Bhutan are 1861.5, 1468.2 and 729.5, respectively).[@R28]

###### 

Cost-effective interventions to control CVD and DM in South Asia

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                                                                                                                                                                                                                   Comparator                                                                                                                                                                                                           Analytical time horizon   Incremental cost per capita (US\$)\*   Incremental effect (DALY averted/QALY gained)\*        ICER, 2017†\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Cost-effectiveness threshold:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \<GDP per capita per QALY=green;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1--3×GDP per capita per QALY=yellow
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------------------------- ------------------------------------------------------ -------------------------------------
  **Primordial prevention**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  *Policy interventions*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Tobacco control strategies (Ortegón *et al*[@R29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Incremental DALYs averted per million population       

   Increased taxation (60%)                                                                                                                                                                                                                      No intervention                                                                                                                                                                                                      Lifetime                  0.27                                   3043                                                   207

   Tax increase+advertisement ban                                                                                                                                                                                                                Increased taxation                                                                                                                                                                                                   Lifetime                  0.1                                    607.0                                                  423

   Tax increase+clean indoor air law                                                                                                                                                                                                             Increased taxation                                                                                                                                                                                                   Lifetime                  0.09                                   574                                                    366

   Tax increase+information/labelling                                                                                                                                                                                                            Tax increase+clean indoor air law                                                                                                                                                                                    Lifetime                  0.11                                   485                                                    529

   Tax increase+advertisement ban+clean indoor air law                                                                                                                                                                                           Tax increase+clean indoor air law                                                                                                                                                                                    Lifetime                  0.12                                   683                                                    410

   Tax increase+advertisement ban+information/labelling                                                                                                                                                                                          Tax increase+advertisement\                                                                                                                                                                                          Lifetime                  0.11                                   485                                                    529
                                                                                                                                                                                                                                                 ban+clean indoor air law                                                                                                                                                                                                                                                                                                                     

   Tax increase+clean indoor air law+advertisement ban+information and labelling                                                                                                                                                                 Tax increase+advertisement\                                                                                                                                                                                          Lifetime                  0.20                                   996.0                                                  468
                                                                                                                                                                                                                                                 ban+clean indoor air law                                                                                                                                                                                                                                                                                                                     

  Tobacco control strategies (Jha *et al*[@R60])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   33% price increase---low-end effect estimate                                                                                                                                                                                                  No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5

   33% price increase---high-end effect estimate                                                                                                                                                                                                 No intervention                                                                                                                                                                                                      Lifetime                                                                                                                71

   Non-price interventions‡ effectiveness 2%--10%---low-end estimate                                                                                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                89

   Non-price interventions‡ effectiveness 2%--10%---high-end estimate                                                                                                                                                                            No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1132

  Complete smoking ban in public places (Donaldson *et al*[@R30])                                                                                                                                                                                Current legislation for partial smoking ban in public places                                                                                                                                                         10 years                  −36 056 957                            17 478 (acute myocardial infarction case averted)      732

  School-based smoking prevention programme (Brown *et al*[@R31])                                                                                                                                                                                No intervention                                                                                                                                                                                                                                175 438.5                              4.52 (QALY/smoker averted)                             4501

  Promoting healthy diet strategies (Cecchini *et al*[@R32])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

   Food labelling                                                                                                                                                                                                                                No intervention                                                                                                                                                                                                      20 years                                                                                                                2220

   Fiscal measure for 100% population                                                                                                                                                                                                            No intervention                                                                                                                                                                                                      50 years                                                                                                                Cost-saving

   Food advertising regulation                                                                                                                                                                                                                   No intervention                                                                                                                                                                                                      50 years                                                                                                                774

   Food labelling                                                                                                                                                                                                                                No intervention                                                                                                                                                                                                      50 years                                                                                                                1810

  Promoting healthy diet strategies (Murray *et al*[@R57])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   Salt reduction through voluntary agreements with industry                                                                                                                                                                                     No intervention                                                                                                                                                                                                      Lifetime                                                                                                                106

   Population-wide reduction in salt intake legislation                                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                54

   Health education through mass media                                                                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                                                                                                                40

   Salt reduction via legislation+health education via mass media                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                49

  Promoting healthy diet strategies (Willett *et al*[@R5])                                                                                                                                                                                                                                                                                                                                                                                                            Lifetime                                                                                                                

   Media campaign to reduce saturated fat content                                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5086

   Substitute 2% of energy from trans fat with polyunsaturated fatty acid (7% coronary artery disease reduction at \$0.5 per adult)                                                                                                              No intervention                                                                                                                                                                                                      Lifetime                                                                                                                104

   Substitute 2% of energy from trans fat with polyunsaturated fatty acid (7% coronary artery disease reduction at \$0.6 per adult)                                                                                                              No intervention                                                                                                                                                                                                      Lifetime                                                                                                                2765

   Substitute 2% of energy from trans fat with polyunsaturated fatty acid (40% coronary artery disease reduction at \$0.5 per adult)                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Substitute 2% of energy from trans fat with polyunsaturated fatty acid (40% coronary artery disease reduction at \$0.6 per adult)                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                376

   Reducing salt content by means of legislation+public education                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                3613

  Blood pressure-lowering strategies (Rodgers *et al*[@R59])                                                                                                                                                                                                                                                                                                                                                                                                          Lifetime                                                                                                                

   Prevention by salt legislation                                                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                49

  Alcohol control strategies (Chisholm *et al*[@R15])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

   Taxation current+25% (alcohol use)                                                                                                                                                                                                            No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Taxation current+50% (alcohol use)                                                                                                                                                                                                            No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Breath testing                                                                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                152

   Highest tax+advertisement ban                                                                                                                                                                                                                 No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5002

  **Primary prevention**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  *Policy interventions*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Universal screening for diabetes and hypertension (Dupka *et al*[@R73])§                                                                                                                                                                                                                                                                                                                                                                                                                                                             DALY averted per person                                

   Current Package of Essential Non-Communicable (PEN) disease interventions programme                                                                                                                                                           No screening                                                                                                                                                                                                         Lifetime                  −77.2                                  0.038                                                  Cost-saving

   Universal screening                                                                                                                                                                                                                           Current WHO-PEN programme                                                                                                                                                                                            Lifetime                  −33.1                                  0.016                                                  Cost-saving

  Screening for GDM to prevent DM (Lohse\                                                                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                  26                                     2.33                                                   16
  *et al*[@R66])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Screening to prevent GDM (Marseille *et al*[@R35])                                                                                                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                  194 358                                120                                                    2317

  Expansion of national insurance to cover primary, secondary and tertiary treatment for CVD (Basu *et al*[@R39])                                                                                                                                                                                                                                                                                                                                                                                                                      Incremental DALY averted per annum                     

   Insurance coverage for primary prevention of CVD                                                                                                                                                                                              Status quo                                                                                                                                                                                                           20 years                  1.19                                   2544.5                                                 528

  *Clinical interventions*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Tobacco control strategies (Jha *et al*[@R60])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Nicotine replacement therapy effectiveness 1%--5%---low-end estimate                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                142

   Nicotine replacement therapy effectiveness 1%--5%---high-end estimate                                                                                                                                                                         No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1880

  To reduce alcohol use (Chisholm *et al*[@R15])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Brief physician advice                                                                                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                175

  CVD prevention strategies (Ortegón *et al*[@R29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Incremental DALYs averted per million population       

  Preventive multidrug treatment (\>5% risk of CVD event)                                                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                  1.97                                   4542                                                   4238

  Preventive multidrug treatment (\>35% risk of CVD event)                                                                                                                                                                                       Preventive multidrug treatment (\>5% risk of CVD event)                                                                                                                                                              Lifetime                  0.38                                   2582                                                   341

  Combination of individual-based drug\                                                                                                                                                                                                          Preventive multidrug treatment (\>5% risk of CVD event)                                                                                                                                                              Lifetime                  1.8                                    1780                                                   2358
  therapy for hypertension and cholesterol\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Combined home health education plus trained general practitioner for hypertension management (Jafar *et al*[@R36])¶                                                                                                                            No intervention                                                                                                                                                                                                      2 years                                                                                                                 48

  Diabetes prevention strategies (Narayan\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  *et al*[@R34])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Smoking cessation (physician counselling and nicotine replacement therapy)                                                                                                                                                                    No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1990.6

   Preconception care for women of reproductive age                                                                                                                                                                                              No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Lifestyle interventions to prevent type 2 diabetes                                                                                                                                                                                            No intervention                                                                                                                                                                                                      Lifetime                                                                                                                163.6

   Metformin intervention to prevent type 2 diabetes                                                                                                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                4962.9

  Lifestyle modification+metformin to prevent type 2 diabetes (Ramachandran *et al*[@R37])                                                                                                                                                                                                                                                                                                                                                                                                                                             Number needed to treat to prevent a case of diabetes   

   Lifestyle modification                                                                                                                                                                                                                        Standard healthcare advice                                                                                                                                                                                           3 years                   164                                    6.4                                                    2302

   Metformin                                                                                                                                                                                                                                     Standard healthcare advice                                                                                                                                                                                           3 years                   159                                    6.9                                                    2396

   Lifestyle modification+metformin                                                                                                                                                                                                              Standard healthcare advice                                                                                                                                                                                           3 years                   209                                    6.5                                                    2973

  **Secondary and tertiary prevention**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  *Policy interventions*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Policies to expand use of drugs for acute myocardial infarction (Megiddo *et al*[@R38])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Acute myocardial infarction treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Aspirin to baseline                                                                                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                                                                                                                0.6

   Aspirin+injection streptokinase                                                                                                                                                                                                               Aspirin to baseline                                                                                                                                                                                                  Lifetime                                                                                                                693

  Acute myocardial infarction prevention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

   Aspirin to baseline                                                                                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                                                                                                                299

   Aspirin+BB                                                                                                                                                                                                                                    Aspirin to baseline                                                                                                                                                                                                  Lifetime                                                                                                                1960

   Aspirin+BB+ACEi                                                                                                                                                                                                                               Aspirin+BB                                                                                                                                                                                                           Lifetime                                                                                                                3120

   Polypill to baseline                                                                                                                                                                                                                          Aspirin+BB+ACEi+statin                                                                                                                                                                                               Lifetime                                                                                                                1904

  Expansion of national insurance to cover primary, secondary and tertiary treatment for CVD (Basu *et al*)[@R39]                                                                                                                                                                                                                                                                                                                                                                                                                      Incremental DALY averted per annum                     

   Insurance coverage for secondary prevention of CVD                                                                                                                                                                                            Status quo                                                                                                                                                                                                           20 years                  0.36                                   147.9                                                  2708

   Insurance coverage for tertiary treatment of CVD                                                                                                                                                                                              Status quo                                                                                                                                                                                                           20 years                  4.68                                   2076.8                                                 2538

  *Clinical interventions*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  CVD treatment strategies (Ortegón *et al*[@R29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Incremental DALYs averted per million population       

   Treatment of CHF with diuretics                                                                                                                                                                                                               No intervention                                                                                                                                                                                                      Lifetime                  0.03                                   402                                                    188.9

   Treatment of CHF with diuretics+exercise training                                                                                                                                                                                             Treatment of CHF with diuretics                                                                                                                                                                                      Lifetime                  0.02                                   60                                                     776.6

   Treatment of CHF with diuretics+exercise training+ACEi                                                                                                                                                                                        Treatment of CHF with diuretics                                                                                                                                                                                      Lifetime                  0.04                                   72                                                     1296.7

   Treatment of CHF with diuretics+exercise training+BB                                                                                                                                                                                          Treatment of CHF with diuretics                                                                                                                                                                                      Lifetime                  0.08                                   95                                                     1963

   Treatment of post-acute ischaemic heart disease and stroke with aspirin, BB, statin                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                  0.03                                   609                                                    114

   Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease with aspirin, BB, statin                                                                                                       No intervention                                                                                                                                                                                                      Lifetime                  0.36                                   1047                                                   799

   Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease with aspirin, BB, statin, ACEi                                                                                                 Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease with aspirin, BB, statin                                                                              Lifetime                  0.37                                   945                                                    914

   Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke with aspirin, BB, statin                                                                                            No intervention                                                                                                                                                                                                      Lifetime                  0.04                                   263                                                    354

   Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke with aspirin, BB, statin+CHF (diuretic, exercise)                                                                   Treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke with aspirin, BB, statin                                                                   Lifetime                  0.26                                   1879                                                   321

   Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, statin)                                       No intervention                                                                                                                                                                                                      Lifetime                  2.57                                   5526                                                   1084

   Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)                                 Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, statin)              Lifetime                  0.04                                   250                                                    373

   Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke (aspirin, BB, statin)                            Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)        Lifetime                  0.04                                   201                                                    464

   Individual-based prevention (hypertension and cholesterol control)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretic, exercise)                                                                  Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke (aspirin, BB, statin)   Lifetime                  −0.23                                  119                                                    Cost-saving

   Individual-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretic, exercise)   Individual-based prevention (hypertension and cholesterol control)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretic, exercise)                                         Lifetime                  0.26                                   437                                                    1387

   Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease (aspirin, BB, statin)                                        No intervention                                                                                                                                                                                                      Lifetime                  1.16                                   4852                                                   557

   Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)                                  Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease (aspirin, BB, statin)               Lifetime                  0.04                                   237                                                    394

   Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)                             Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)         Lifetime                  0.04                                   178                                                    524

   Combination drug treatment (\>25% risk of CVD event)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretics, exercise)                                                                               Combination drug treatment (\>25% risk of CVD event)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)    Lifetime                  −0.23                                  32                                                     Cost-saving

   Preventive multidrug treatment for \>25% risk of CVD event+multidrug treatment of acute myocardial infarction or post-acute ischaemic heart disease and stroke+diuretics and exercise for CHF                                                 Combination drug treatment (\>25% risk of CVD event)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretics, exercise)                                                      Lifetime                  0.26                                   558                                                    1086

   Combination drug treatment (\>35% risk of CVD event)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretics, exercise)                                                                               Combination drug treatment (\>35% risk of CVD event)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretics, exercise)                                                      Lifetime                  −0.23                                  31                                                     Cost-saving

   Preventive multidrug treatment for \>35% risk of CVD event+multidrug treatment of acute myocardial infarction or post-acute ischaemic heart disease and stroke+diuretics and exercise for CHF                                                 Combination drug treatment (\>35% risk of CVD event)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretics, exercise)                                                      Lifetime                  0.26                                   630                                                    963

  CVD treatment strategies (Murray *et al*[@R57])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

   Treatment of SBP above 160 mm Hg with BB and diuretic                                                                                                                                                                                         No intervention                                                                                                                                                                                                      Lifetime                                                                                                                103.2

   Treatment of SBP above 140 mm Hg with BB and diuretic                                                                                                                                                                                         No intervention                                                                                                                                                                                                      Lifetime                                                                                                                257.9

   Treatment with statins for total cholesterol concentrations above education 6.2 mmol/L                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                134.7

   Treatment with statins for total cholesterol concentrations above education 5.7 mmol/L                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                203.5

   Treatment of SBP above 140 mm Hg with BB and diuretics and with statins for total cholesterol concentrations above 6.2 mmol/L                                                                                                                 No intervention                                                                                                                                                                                                      Lifetime                                                                                                                240.7

   Multiple drug therapy in \>35% CV risk over 10 years                                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Multiple drug therapy in \>25% CV risk over 10 years                                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                94.6

   Multiple drug therapy in \>15% CV risk over 10 years                                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                137.5

   Multiple drug therapy in \>5% CV risk over 10 years                                                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                                                                                                                220.7

  CVD treatment and secondary prevention (Gaziano *et al*[@R43])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Medical therapy for acute myocardial infarction with aspirin                                                                                                                                                                                  No intervention                                                                                                                                                                                                      Lifetime                                                                                                                25.8

   Medical therapy for acute myocardial infarction with aspirin+BB                                                                                                                                                                               No intervention                                                                                                                                                                                                      Lifetime                                                                                                                31.5

   Medical therapy for acute myocardial infarction with aspirin+BB+streptokinase                                                                                                                                                                 No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1828.8

   Medical therapy (aspirin+BB) for ischaemic heart disease, having hospital access                                                                                                                                                              No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Medical therapy (aspirin+BB+ACEi) for ischaemic heart disease, having hospital access                                                                                                                                                         No intervention                                                                                                                                                                                                      Lifetime                                                                                                                2049.5

   Medical therapy (aspirin+BB+ACEi+statin) for ischaemic heart disease, having hospital access                                                                                                                                                  No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5214.2

   Medical therapy (aspirin+BB) for ischaemic heart disease, limited hospital access                                                                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1106.4

   Medical therapy (aspirin+BB+ACEi) for ischaemic heart disease, limited hospital access                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                2373.4

   ACEi for CHF, hospital access                                                                                                                                                                                                                 Baseline of diuretics                                                                                                                                                                                                Lifetime                                                                                                                Cost-saving

   ACEi, BB (metoprolol) for CHF, hospital access                                                                                                                                                                                                Baseline of diuretics                                                                                                                                                                                                Lifetime                                                                                                                627.7

   ACEi for CHF, limited hospital access                                                                                                                                                                                                         Baseline of diuretics                                                                                                                                                                                                Lifetime                                                                                                                71.6

   ACEi, BB (metoprolol) for CHF, limited hospital access                                                                                                                                                                                        Baseline of diuretics                                                                                                                                                                                                Lifetime                                                                                                                782.5

  Blood pressure-lowering strategies (Rodgers *et al*[@R59])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

   Multidrug regimen (aspirin, a BB, a thiazide diuretic, an ACEi and a statin) in 35% CV risk over 10 years                                                                                                                                     No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1827

   Multidrug regimen (aspirin, a BB, a thiazide diuretic, an ACEi and a statin) in 25% CV risk over 10 years                                                                                                                                     No intervention                                                                                                                                                                                                      Lifetime                                                                                                                3408.6

   Multidrug regimen (aspirin, a BB, a thiazide diuretic, an ACEi and a statin) in 15% CV risk over 10 years                                                                                                                                     No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5268.2

  Treat-to-target, benefit-based tailored treatment strategy vs hybrid strategy for lowering CVD risk (Basu *et al*[@R78])                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   People treated identically by all three strategies                                                                                                                                                                                            No intervention                                                                                                                                                                                                      10 years                                                                                                                383.7

   People treated most intensively by treat-to-target                                                                                                                                                                                            No intervention                                                                                                                                                                                                      10 years                                                                                                                432.1

   People treated most intensively by benefit-based tailored treatment                                                                                                                                                                           No intervention                                                                                                                                                                                                      10 years                                                                                                                206.1

   People treated most intensively by hybrid                                                                                                                                                                                                     No intervention                                                                                                                                                                                                      10 years                                                                                                                384.4

  Prehospital ECG for accurate referral and timely access to reperfusion (Schulman-Marcus *et al*[@R40])                                                                                                                                         No ECG-based referral in case of chest pain                                                                                                                                                                          Lifetime                  0.15                                   0.012 (QALY gained)                                    26.1

  Diabetes treatment strategies (Narayan\                                                                                                                                                                                                                                                                                                                                                                                                                             Lifetime                                                                                                                
  *et al*[@R34])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Glycaemic control in people with HbA1c \>9% (insulin, oral glucose-lowering agents, diet and exercise)                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Blood pressure control in people with \>160/95 mm Hg                                                                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Foot care in people with a high risk of ulcers                                                                                                                                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                Cost-saving

   Influenza vaccination among elderly                                                                                                                                                                                                           No intervention                                                                                                                                                                                                      Lifetime                                                                                                                490.8

   Annual eye examination                                                                                                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                954.4

   ACEi use for people with diabetes                                                                                                                                                                                                             No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1390.7

   Intensive glucose control for people with HbA1c \>8% (insulin, oral glucose-lowering agents or both)                                                                                                                                          No intervention                                                                                                                                                                                                      Lifetime                                                                                                                5453.7

  Treatment of diabetes and its complications (Ortegón *et al*[@R29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Incremental DALYs averted per million population       

   Standard glycaemic control                                                                                                                                                                                                                    No intervention                                                                                                                                                                                                      Lifetime                  0.82                                   1717                                                   1115

   Retinopathy screening and photocoagulation therapy                                                                                                                                                                                            No intervention                                                                                                                                                                                                      Lifetime                  0.32                                   1891                                                   396.4

   Standard glycaemic control+retinopathy\                                                                                                                                                                                                       Intensive glycaemic control+neuropathy screening                                                                                                                                                                     Lifetime                  −0.65                                  213                                                    Cost-saving
   screening+neuropathy screening                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  BIAsp 30±oral glucose-lowering drugs (Gupta *et al*[@R41])                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Incremental QALY gained per annum                      

   BIAsp 30                                                                                                                                                                                                                                      BHI 30 or IGlar                                                                                                                                                                                                      30 years                  868.496                                2.52                                                   412.9

   BIAsp 30                                                                                                                                                                                                                                      NPH insulin                                                                                                                                                                                                          30 years                  −2524.192                              2.82                                                   Cost-saving

   BIAsp 30                                                                                                                                                                                                                                      IGlar                                                                                                                                                                                                                30 years                  527.232                                2.74                                                   228.8

   BIAsp 30                                                                                                                                                                                                                                      BHI 30 or IGlar                                                                                                                                                                                                      1 year                    123.264                                0.21                                                   684.2

   BIAsp 30                                                                                                                                                                                                                                      IGlar                                                                                                                                                                                                                1 year                    93.984                                 0.23                                                   487.2

  Basal insulin vs oral glucose-lowering drugs (Home *et al*[@R75])                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Incremental QALY gained per annum                      

   Basal insulin treatment with insulin detemir                                                                                                                                                                                                  Oral glucose-lowering drugs                                                                                                                                                                                          30 years                  3510.36                                4.97                                                   834.1

   Basal insulin treatment with insulin detemir                                                                                                                                                                                                  Oral glucose-lowering drugs                                                                                                                                                                                          1 year                    338.796                                0.322                                                  1243.4

  Telemedicine screening+diabetic retinopathy treatment (Rachapelle *et al*[@R27])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Health system perspective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Incremental QALY gained per annum                      

   Screening once in a lifetime                                                                                                                                                                                                                  No screening                                                                                                                                                                                                         25 years                  6.5                                    0.0049                                                 2214.1

   Screening twice in a lifetime                                                                                                                                                                                                                 No screening                                                                                                                                                                                                         25 years                  5.3                                    0.0039                                                 2252.7

   Screening every 5 years                                                                                                                                                                                                                       No screening                                                                                                                                                                                                         25 years                  19.6                                   0.0097                                                 3400.1

   Screening every 3 years                                                                                                                                                                                                                       No screening                                                                                                                                                                                                         25 years                  17.4                                   0.0084                                                 3411.8

   Screening every 2 years                                                                                                                                                                                                                       No screening                                                                                                                                                                                                         25 years                  18.4                                   0.0075                                                 4084.5

  Societal perspective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   Screening once in a lifetime                                                                                                                                                                                                                  No screening                                                                                                                                                                                                         25 years                  13.2                                   0.0049                                                 4515.6

   Screening twice in a lifetime                                                                                                                                                                                                                 No screening                                                                                                                                                                                                         25 years                  9.7                                    0.0039                                                 4151.6

   Screening every 5 years                                                                                                                                                                                                                       No screening                                                                                                                                                                                                         25 years                  30.3                                   0.0097                                                 5257

  **Combination of primordial, primary, secondary and tertiary prevention**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Interventions to reduce hazardous alcohol use (Chisholm *et al*[@R15])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

   Highest tax+advertisement ban+brief advice                                                                                                                                                                                                    No intervention                                                                                                                                                                                                      Lifetime                                                                                                                2562.7

  Blood pressure-lowering strategies (Rodgers *et al*[@R59])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

   Prevention by salt legislation+health education                                                                                                                                                                                               No intervention                                                                                                                                                                                                      Lifetime                                                                                                                87.2

   Treatment with aspirin, BB, and a statin+salt legislation+health education in 35% CV risk over 10 years                                                                                                                                       No intervention                                                                                                                                                                                                      Lifetime                                                                                                                362.6

   Treatment with aspirin, BB, and a statin+salt legislation+health education in 25% CV risk over 10 years                                                                                                                                       No intervention                                                                                                                                                                                                      Lifetime                                                                                                                1576

   Treatment with aspirin, BB, and a statin+salt legislation+health education in 15% CV risk over 10 year                                                                                                                                        No intervention                                                                                                                                                                                                      Lifetime                                                                                                                3054

  Intervention for CVD prevention and treatment (Murray *et al*[@R57])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   Combination of legislation for salt reduction, health education and treatment of individuals with combined CV risk of 35% with statin, diuretic, BB and aspirin                                                                               No intervention                                                                                                                                                                                                      Lifetime                                                                                                                63

   Combination of legislation for salt reduction, health education and treatment of individuals with combined CV risk of 25% with statin, diuretic, BB and aspirin                                                                               No intervention                                                                                                                                                                                                      Lifetime                                                                                                                89

   Combination of legislation for salt reduction, health education and treatment of individuals with combined CV risk of 15% with statin, diuretic, BB and aspirin                                                                               No intervention                                                                                                                                                                                                      Lifetime                                                                                                                132

   Combination of legislation for salt reduction, health education and treatment of individuals with combined CV risk of 5% with statin, diuretic, BB and aspirin                                                                                No intervention                                                                                                                                                                                                      Lifetime                                                                                                                212

  CVD prevention and treatment strategies (Ortegón *et al*[@R29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Incremental DALYs averted per million population       

   Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, statin)                                       No intervention                                                                                                                                                                                                      Lifetime                  0.55                                   2376                                                   538

   Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)                                 Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, statin)              Lifetime                  0.04                                   285                                                    326

   Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease and stroke (aspirin, BB, statin)                            Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute ischaemic heart disease (aspirin, BB, ACEi, statin)        Lifetime                  0.04                                   246                                                    380

   Population-based prevention (hypertension and cholesterol control)+treatment of acute myocardial infarction (aspirin, BB, ACEi, streptokinase)+post-acute Ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretic, exercise)   Population-based prevention (hypertension and cholesterol control)+treatment of post-acute ischaemic heart disease and stroke (aspirin, BB, statin)+CHF (diuretic, exercise)                                         Lifetime                  0.26                                   646                                                    937

  Expansion of national insurance to cover primary, secondary and tertiary treatment for CVD (Basu *et al*)[@R39]                                                                                                                                                                                                                                                                                                                                                                                                                      Incremental DALY averted per annum                     

   Insurance coverage for primary+secondary prevention of CVD                                                                                                                                                                                    Primary prevention only                                                                                                                                                                                              20 years                  0.35                                   145.0                                                  2739

   Insurance coverage for primary+tertiary prevention of CVD                                                                                                                                                                                     Primary prevention only                                                                                                                                                                                              20 years                  4.67                                   2084.6                                                 2525
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GDP per capita (US\$, 2016) for India, Pakistan and Bhutan are 1861.5, 1468.2 and 729.5, respectively.

\*Values refer to original study period.

†Conversion to current year, based on midyear consumer price index inflation rates.

‡Non-price interventions to reduce tobacco use:

--protection from exposure to tobacco smoke

*--*regulation of the contents of tobacco products

*--*regulation of tobacco product disclosures

*--*packaging and labelling of tobacco products

*--*education, communication, training and public awareness

*--*tobacco advertising, promotion and sponsorship

*--*demand reduction measures concerning tobacco dependence and cessation.

§Conducted in Bhutan.

¶Conducted in Pakistan.

ACEi, ACE inhibitors; BB, beta-blockers (blood pressure-lowering agents; BHI, biphasic human insulin; BIAsp 30, biphasic insulin aspart 30; CHF, congestive heart failure; CV, cardiovascular; CVD, cardiovascular diseases; DALY, disability-adjusted life years; DM, diabetes mellitus; GDM, gestation diabetes mellitus; GDP, gross domestic product; HbA1c, glycated haemoglobin; ICER, incremental cost-effectiveness ratio; IGlar, insulin glargine; QALY, quality-adjusted life years; NPH, neutral protamine Hagedorn; SBP, systolic blood pressure.

Primordial prevention {#s2f}
---------------------

We found that a multicomponent population-level policy intervention consisting of increase in tobacco tax, clean indoor air law, advertisement ban and information/labelling are all highly cost-effective than increased tobacco tax alone (\<1×GDP per capita per DALY averted).[@R29] Addition of 'nicotine replacement therapy', 'brief advice' or 'physician counselling' to the combination strategy for tobacco control was not cost-effective (\>3×GDP per capita per DALY averted).[@R29] Complete smoking ban in public places is also highly cost-effective in terms of life years gained and acute myocardial infarction averted.[@R30] School-based smoking prevention programme as evaluated in a cluster randomised trial in India[@R31] was found to be cost-effective (1--3×GDP per capita per QALY gained). Salt reduction by legislation was cost-effective (1--3×GDP per capita per DALY averted).[@R29] Substitution of trans fat with polyunsaturated fatty acids was cost-effective compared with null scenario (no intervention) per DALY averted.[@R32] Media campaign to reduce saturated fat content was also cost-effective per DALY averted.[@R32] A combined intervention of salt reduction by means of legislation together with public education campaign is cost-effective too.[@R32] Alcohol taxation combined with advertisement ban was the most cost-effective strategy for alcohol control.[@R15]

Primary prevention {#s2g}
------------------

A 2015 modelling study conducted in Bhutan demonstrated that universal screening for diabetes and hypertension was highly cost-effective compared with no screening (\<1×GDP per capita per QALY gained).[@R33] Another 2006 modelling study from India[@R34] showed that screening undiagnosed diabetes and treating those who test positive were not cost-effective, with an ICER of US\$11 671 per DALY averted (ie, \>3×GDP per capita for India), suggesting that screening for diabetes alone was not cost-effective and it should be supplemented with other risk factors, for example, hypertension. Other factors that could have influenced conflicting results include different health system-related cost, different model structure/model parameters, disease prevalence and time period.

Screening for gestational DM to prevent DM was also cost-effective compared with no screening.[@R35]

Among clinical interventions, preventive multidrug treatment provided to those at \>35% cardiovascular risk vs 5% cardiovascular risk over 10 years was more cost-effective.[@R29] Combined strategy of home health education plus trained general physician for hypertension management was highly cost-effective per DALY averted than individual strategies or no intervention in Pakistan.[@R36]

Lifestyle modification (weight reduction, increased activity and healthy diet) was most cost-effective for prevention of DM, followed by metformin alone and combination of lifestyle modification plus metformin (1--3×GDP per capita).[@R37]

Secondary and tertiary prevention {#s2h}
---------------------------------

Policies to expand access of drugs for acute myocardial infarction prevention and treatment were cost-effective per DALY averted.[@R38] Also, expansion of national insurance to cover secondary or tertiary prevention of CVD was most cost-effective per QALY gained compared with status quo.[@R39] Clinical interventions for secondary prevention of CVD are mostly cost-effective per DALY averted.[@R29] ECG-based doctor referral to cardiac care unit versus no 'ECG use' was cost-effective per QALY gained.[@R40]

Many strategies for DM treatment and secondary prevention of macrovascular and microvascular complications were found to be highly cost-effective or cost-effective. Examples of highly cost-effective interventions are glycaemic control in people with glycated haemoglobin (A1c) \>9% with insulin, oral glucose-lowering drugs, diet and exercise, BP control in people with \>165/95 mm Hg, and foot care in people with high risk of ulcers (\<1×GDP per capita per DALY averted).[@R34] Basal insulin treatment versus oral glucose-lowering drugs was highly cost-effective (\<1×GDP per capita per QALY gained).[@R41] Diabetic retinopathy screening every 2--5 years versus no screening was cost-effective (1--3×GDP per capita per QALY gained).[@R27]

Combination of primordial, primary, secondary and tertiary prevention {#s2i}
---------------------------------------------------------------------

Multicomponent strategies of salt reduction through legislation (increase tax), health education, plus treatment of individuals at 35% cardiovascular risk with statin, diuretic, beta-blockers and aspirin were highly cost-effective, followed by similar strategy in those at 25% or 15% cardiovascular risk over 10 years.[@R29] Policy measures such as expansion of insurance coverage for primary, secondary and tertiary prevention of CVD were also cost-effective (1--3×GDP per capita per DALY averted).[@R39]

Interventions that resulted in ICER\>3×GDP per capita or were dominated by other highly cost-effective strategies are presented in online [supplementary table 1](#SP1){ref-type="supplementary-material"}. Significant heterogeneity in analytical framework and outcome measures used in these studies restricted meta-analysis and direct ranking of the interventions by their degree of cost-effectiveness.

Discussion {#s3}
==========

This review finds that, with some exceptions, most interventions to control CVD and DM were cost-effective (\<1--3×GDP per capita per QALY gained or DALY averted), although the strength of evidence (and risk of bias) varied across economic evaluations based on observational studies, RCTs and decision models. Most interventions were cost-effective because of the large benefits in DALY averted or QALY gained at a marginal increase in cost per capita (\$). These results should motivate decision makers to invest in primordial prevention strategies (increased tobacco tax, salt reduction by legislation, food labelling and food advertising regulation), and primary and secondary prevention interventions: multidrug therapy for CVD prevention and treatment in high-risk groups, lifestyle modification and metformin for diabetes prevention, and screening for diabetes complications every 2--5 years. Although detecting and treating diabetes earlier can prevent future complications and their associated medical costs, such savings were shown to be relatively small.[@R34] An alternative to broad screening is to focus on targeted screening, that is, screening only persons with additional risk factors, such as hypertension and obesity. Such targeted screening was shown to be highly cost-effective or cost-saving when compared with no screening.[@R33]

Choice of comparator is an important decision when evaluating ICER of new interventions. In general, modelling studies that used the WHO-CHOICE method have reported average cost-effectiveness ratio against the null scenario (no intervention). In reality, however, this does not seem plausible because null scenario will not always reflect zero costs and zero effects. Also, these studies first identified the most cost-effective intervention among a group of strategies (eg, tobacco control, CVD prevention and treatment, or diabetes prevention and treatment) versus null scenario, then compared it with the next most cost-effective intervention.[@R29] In many of such analysis, because the description of comparator was not clearly specified, the reported ICERs look ambiguous and changing the 'comparator' might produce a different ICER.

In our formal appraisal of the methodological quality of studies, we observed limitations in documentation of main study details, for example, chosen study perspective, sources of cost data and analytical time horizon. In addition, significant number of studies failed to provide details on units of resource use, costing year, currencies and other economic aspects. Since the discount rate used has an impact on cost-effectiveness estimates, the zero-discount rate applied in some studies is deeply concerning. In reality, however, every economic evaluation will contain some degree of uncertainty or imprecision. While one-way sensitivity analysis is helpful in understanding the impact of assumptions about one input parameter, multi-way sensitivity analysis offers a robust method to explore the uncertainty concerning more than one input parameters, but few studies reported results using this technique.

In terms of comparing results of this review with other contemporary reviews, we found cost-effectiveness evidence on a large number of preventive strategies, which is inconsistent with a previous review that examined the economic evaluation from Health Economic Evaluation Database[@R42] and concluded that only 10% of all evaluations assessed preventive care. The greater number of preventive strategies found in our review could be due to the development of the WHO-CHOICE programme[@R26] and the release of the DCPP2 in April 2006.[@R43]

Although cost-effectiveness evidence is available for 301 interventions to control CVD or DM, most of this evidence is based on decision models, which used data (annual risk of disease progression and intervention benefits) from Western countries. Most decision model studies have derived treatment effects from either meta-analysis of RCTs if available for an intervention or single RCT if meta-analysis is not available. However, the limited representation of South Asian populations in those RCTs remains an important concern. Therefore, our review highlights an alarming paucity of local research data to conduct high-quality economic evaluations and reflect the concerns of others in the field that large research gaps do remain in the area of health economic analysis in South Asian countries.[@R44] Also, data from countries other than India are sparse. This is likely a reflection of research capacity in these countries, which needs to be addressed as a priority. Although the countries in South Asia are frequently grouped together, various countries in this region have substantially different health systems, health literacy, health indices, and hence healthcare needs. Understanding the differences be the countries is critical for policy makers, and therefore additional economic evaluations are urgently needed from other South Asian countries.

Strengths and limitations {#s3a}
-------------------------

This review has several strengths. This is the first study, to our knowledge, to include all types of interventions (policy, clinical and behavioural) that affect CVD or DM in South Asia. We considered all possible interventions (primordial, primary, secondary and tertiary prevention) to control CVD and DM together in this systematic review, primarily because policy makers have to choose between different options (competing priorities) for appropriate resource allocation, and as such a narrow economic research question is really not helpful for the systematic review, which intends to inform the process. We have used explicitly stated methods (protocol paper published)[@R19] and standard checklists to assess methodological quality of studies. Recently, new methods have been proposed by researchers that can be applied to review decision model studies.[@R45] However, use of new criteria would not change the findings of this review because these points have been covered broadly by the three popular checklists that we used in this review. Also, new methods have been proposed to estimate country-specific threshold for cost-effectiveness based on opportunity cost (health forgone) with investment in new intervention.[@R46] But we preferred to present the findings based on WHO guidelines[@R25] and for a lower threshold, that is, 1×GDP per capita. Moreover, the incremental cost and incremental benefits have been shown for all interventions (where available) so the decision makers or clinicians can make considerations based on their own willingness to pay threshold or budgetary constraints.

This review is not without limitations. First, the search was restricted to English-language publications performed as of August 2016. But this would not be a major problem because all the South Asian countries mostly publish research in English. Second, we excluded unpublished and 'grey' literature as we wanted to include studies that have undergone peer review process. We believe though that no major studies that can change the results of this review have been missed.

The review findings should be interpreted with caution because most of the cost-effectiveness studies were based on decision models. Although good-quality decision modelling study can provide information at a lower cost than RCT-based economic evaluations, models are based on assumptions and represent a simplification of---and therefore might depart from---reality. Furthermore, interventions that were highlighted as cost-effective (yellow) or highly cost-effective or dominant (green) analysed using the WHO-CHOICE framework could be reassessed by local agencies, particularly with regard to budget impact and also their cost-effectiveness, taking into account local costs and willingness to pay threshold value, similar to the work carried out by the Health Intervention and Technology Assessment Program in Thailand over the past decade.[@R47]

Future research directions {#s3b}
--------------------------

We have identified key research gaps in this review. Interventions involving multisectoral approach and policies for change in drug prices or devices (stents prices) have not been evaluated for their cost-effectiveness. The cost-effectiveness of these interventions should be assessed.

A few recommendations to advance the research on economic evaluations in the region are as follows. First, future studies need to take a broader societal perspective for analysis and present cost data in disaggregated form (resource consumption and unit costs, separately). Second, more research is needed to support the causes of variation among costs, effects and cost-effectiveness data on the universal screening of diabetes and/or hypertension. Third, research should focus on assessing the generalisability of cost-effectiveness analysis results within and between countries. Lastly, future cost-effectiveness analysis studies should adhere to international guidelines proposed by the WHO,[@R25] International Society for Pharmacoeconomics and Outcomes Research,[@R48] and the recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine[@R52] as a benchmark for design, conduct and reporting.

Conclusion {#s4}
==========

The existing economic evidence base from South Asia should motivate policy makers to mobilise resource allocation towards the most cost-effective interventions identified in this review to curb the epidemic of CVD and DM in the region. Also, there is an urgent need to invest in health technology assessment and policy evaluations in South Asia using local research data.
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